Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells

Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs

“…Some prior reports have indicated a relationship between single agent use and immunogenicity of cancer cell lines (i.e., colon, breast, and stomach cancers) (Fisk and Ioannides 1998;Hayashi et al 1996;Maas et al 1991;Prete et al 1996). However, we have studied, for the first time, anti-tumor immunogenicity of colorectal cancer cell lines using three anti-cancer agents including SN-38.…”

“…Several reports have previously indicated that certain standard chemotherapeutic agents, e.g., 5-FU, cisdiamminedichloroplatinum(II) (CDDP), induce a similar response to cancer cells (Hayashi et al 1996;Maas et al 1991;Prete et al 1996). Moreover, it has been suggested that post-chemotherapeutic cancer cells exhibit increased expression of MHC class I and TAA (Cappelletti et al 2000;Fisk and Ioannides 1998;Hayashi et al 1996). Taking this into consideration, one may expect that the use of standard chemotherapy may augment immune surveillance against cancer cells via endogenous induction of particular antigens.…”

“…Enhancement of TAA expression may facilitate augmentation of antibody-dependent cellular cytotoxicity (ADCC), or improve tumor detection via conjugated monoclonal antibodies (Greiner et al 1987). Several reports have previously indicated that certain standard chemotherapeutic agents, e.g., 5-FU, cisdiamminedichloroplatinum(II) (CDDP), induce a similar response to cancer cells (Hayashi et al 1996;Maas et al 1991;Prete et al 1996). Moreover, it has been suggested that post-chemotherapeutic cancer cells exhibit increased expression of MHC class I and TAA (Cappelletti et al 2000;Fisk and Ioannides 1998;Hayashi et al 1996).…”

Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics

“…Indeed at low doses Cyclophosphamide inhibited the growth of murine hepatoma MH129 in immunocompetent but not in immunodepleted mice and the inhibition did not occur in mice given CD4+CD25+ T cells [166]. In this study the interesting observation was made that the administration of low dose Cyclophosphamide was more effective in causing depletion of CD4+CD25+ cells when given after tumor inoculation than when given before tumor inoculation: as the authors stated [166], this finding is of relevance to clinical Phenylalinine mustard + [147,[188][189][190][191] Busulfan + + [148,169,[192][193][194] Nitrosoureas + + [148,[195][196][197][198][199][200][201][202] Cis Platinum + + [170,203,204,205,[206][207][208][209][210][211][212][213][214][215] Difluoromethylornithine + + [280][281][282][283][284][285] trials of chemotherapy and immunotherapy combinations. In this study the interesting observation was made that the administration of low dose Cyclophosphamide was more effective in causing depletion of CD4+CD25+ cells when given after tumor inoculation than when given ...…”

“…Early studies indicated that CDDP and one of its analogs augmented the primary cell-mediated cytotoxic response in a mixed lymphocyte tumor cells culture both when the agents were added to the culture and when they were administered to spleen donor mice 1-5 days prior to spleen removal and sensitization of spleen cells in the mixed cultures [204]. The increase of HLA antigens after incubation of tumor cells with CDDP was also demonstrated measuring the AC-81 adenocarcinoma-associated antigen on gastric cancer cell line KATO-3 [208], increase which resulted in increased susceptibility of the cancer cells to LAK cells and T-lymphocytes cytotoxicity. The increase of HLA antigens after incubation of tumor cells with CDDP was also demonstrated measuring the AC-81 adenocarcinoma-associated antigen on gastric cancer cell line KATO-3 [208], increase which resulted in increased susceptibility of the cancer cells to LAK cells and T-lymphocytes cytotoxicity.…”